Adverse events associated with tezepelumab: a safety analysis of clinical trials and a pharmacovigilance system
This study represents the largest report to date on tezepelumab-related AEs, providing valuable insights into the potential side effects of tezepelumab. This work is crucial for the broader clinical application of this novel biologic and improving outcomes for patients with severe asthma.
Authors
- Xiaoyan Zhu (ORCID: https://orcid.org/0000-0002-1078-4123)
- Pengdou Zheng
- Fengqin Zhang (ORCID: https://orcid.org/0000-0001-9479-2456)
- Lingling Wang (ORCID: https://orcid.org/0000-0003-3576-1080)
- Wei Liu (ORCID: https://orcid.org/0000-0001-5163-9742)
- Ling Zhou (ORCID: https://orcid.org/0000-0002-4499-7565)
- Yuchen Huang (ORCID: https://orcid.org/0009-0006-8138-5740)
- Huiguo Liu (ORCID: https://orcid.org/0000-0001-9229-4840)
- Wenhui Liao (ORCID: https://orcid.org/0000-0001-8015-6918)
- Zhenyu Mao
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1080/14740338.2024.2416921
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- Health Commission of Hubei Province
- National Natural Science Foundation of China